Occam’s enduring relationship with LabGenius, a UK-based AI-enabled protein drug discovery platform company, has yielded a second C-suite placement in Leo Wossnig as CTO. Leo will work in close partnership with Gino Van Heeke, the CSO, whom Occam placed as CSO in 2021.

Wossnig comes to LabGenius by way of Odyssey Therapeutics following the acquisition of his company, Rahko, a leading quantum machine learning company which Leo co-founded and led as CEO.

In Wossnig, LabGenius captures an intellectual heavyweight, content expert and accomplished entrepreneur with demonstrated success building and leveraging sophisticated computational technologies in the service of expediting drug discovery at scale.